Pawel Mielnik1, Joseph Sexton2, Elisabeth Lie2, Gunnstein Bakland3, Liz P Loli4, Eirik K Kristianslund2, Erik Rødevand5, Åse S Lexberg6, Tore K Kvien2,7. 1. Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde, Svanehaugevegen 1, 6812, Førde, Norway. pawel.franciszek.mielnik@helse-forde.no. 2. Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. 3. Department of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway. 4. Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway. 5. Department of Rheumatology, St. Olavs Hospital, Trondheim, Norway. 6. Department of Rheumatology, Vestre Viken/Drammen Hospital, Drammen, Norway. 7. Faculty of Medicine, University of Oslo, Oslo, Norway.
Abstract
OBJECTIVE: The objective of this study was to compare the efficacy and safety of rituximab in older vs younger patients with rheumatoid arthritis. METHODS: Data on 367 patients with rheumatoid arthritis treated with rituximab in the Norwegian Disease-Modifying Antirheumatic Drug (NOR-DMARD) register were analysed, comparing patients aged ≥ 65 years (n = 91) with patients aged < 65 years (n = 276). Drug survival was compared using a Kaplan-Meier analysis and Cox proportional hazard models. Disease activity, as assessed by the Disease Activity Score based on 28 joints and erythrocyte sedimentation rate (DAS28-ESR) and the Simplified Disease Activity Index, was analysed with linear mixed models. The occurrence of adverse events was analysed by quasi-Poisson regression models. RESULTS: Drug survival was similar in the two age groups. The proportion of patients who remained taking rituximab over 2 years was 72% in those under aged 65 years vs 74% in those aged ≥ 65 years. No statistically significant association with age was found for drug survival in either the unadjusted (hazard ratio 1.13, p = 0.65) or adjusted Cox proportional hazard analyses for the model with DAS28-ESR as a confounder (effect size 1.11, p = 0.73). Models including the Simplified Disease Activity Index instead of DAS28-ESR yielded similar results. Age was furthermore not significantly associated with disease activity over time, although there was a tendency towards a poorer response in older patients. In the older age group, there was a higher incidence of pneumonia (107 vs 51 per 1000 patient-years) and other serious infections (142 vs 66 per 1000 patient-years). CONCLUSIONS: Rituximab is a reasonable therapeutic option for older patients with rheumatoid arthritis although vigilance is needed with regard to the infection profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01581294.
OBJECTIVE: The objective of this study was to compare the efficacy and safety of rituximab in older vs younger patients with rheumatoid arthritis. METHODS: Data on 367 patients with rheumatoid arthritis treated with rituximab in the Norwegian Disease-Modifying Antirheumatic Drug (NOR-DMARD) register were analysed, comparing patients aged ≥ 65 years (n = 91) with patients aged < 65 years (n = 276). Drug survival was compared using a Kaplan-Meier analysis and Cox proportional hazard models. Disease activity, as assessed by the Disease Activity Score based on 28 joints and erythrocyte sedimentation rate (DAS28-ESR) and the Simplified Disease Activity Index, was analysed with linear mixed models. The occurrence of adverse events was analysed by quasi-Poisson regression models. RESULTS: Drug survival was similar in the two age groups. The proportion of patients who remained taking rituximab over 2 years was 72% in those under aged 65 years vs 74% in those aged ≥ 65 years. No statistically significant association with age was found for drug survival in either the unadjusted (hazard ratio 1.13, p = 0.65) or adjusted Cox proportional hazard analyses for the model with DAS28-ESR as a confounder (effect size 1.11, p = 0.73). Models including the Simplified Disease Activity Index instead of DAS28-ESR yielded similar results. Age was furthermore not significantly associated with disease activity over time, although there was a tendency towards a poorer response in older patients. In the older age group, there was a higher incidence of pneumonia (107 vs 51 per 1000 patient-years) and other serious infections (142 vs 66 per 1000 patient-years). CONCLUSIONS:Rituximab is a reasonable therapeutic option for older patients with rheumatoid arthritis although vigilance is needed with regard to the infection profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01581294.
Authors: H Chevillotte-Maillard; P Ornetti; R Mistrih; C Sidot; J Dupuis; J-A Dellas; C Tavernier; J F Maillefert Journal: Rheumatology (Oxford) Date: 2005-02-10 Impact factor: 7.580
Authors: Kalle Jyri Aaltonen; Jaana Tuulikki Joensuu; Liisa Virkki; Tuulikki Sokka; Pasi Aronen; Heikki Relas; Heikki Valleala; Vappu Rantalaiho; Laura Pirilä; Kari Puolakka; Tea Uusitalo; Marja Blom; Yrjö Tapio Konttinen; Dan Nordström Journal: J Rheumatol Date: 2015-01-15 Impact factor: 4.666
Authors: Johan Askling; C Michael Fored; Lena Brandt; Eva Baecklund; Lennart Bertilsson; Nils Feltelius; Lars Cöster; Pierre Geborek; Lennart T Jacobsson; Staffan Lindblad; Jörgen Lysholm; Solbritt Rantapää-Dahlqvist; Tore Saxne; Ronald F van Vollenhoven; Lars Klareskog Journal: Ann Rheum Dis Date: 2007-01-29 Impact factor: 19.103
Authors: Joan M Bathon; Roy M Fleischmann; Désirée Van der Heijde; John R Tesser; Paul M Peloso; Yun Chon; Barbara White Journal: J Rheumatol Date: 2006-02 Impact factor: 4.666
Authors: Tamas Fulop; Anis Larbi; Gilles Dupuis; Aurélie Le Page; Eric H Frost; Alan A Cohen; Jacek M Witkowski; Claudio Franceschi Journal: Front Immunol Date: 2018-01-10 Impact factor: 7.561